垂体神经内分泌肿瘤分类研究进展
Progress in the Classification of Pituitary Neuroendocrine Tumors
DOI: 10.12677/ACM.2023.1371525, PDF,   
作者: 严佳乐, 苏晓梅, 马晓梅*：新疆医科大学第三临床医学院(附属肿瘤医院)病理科，新疆 乌鲁木齐
关键词: 垂体神经内分泌瘤；垂体腺瘤；垂体母细胞瘤；垂体细胞瘤；Pituitary Neuroendocrine Tumor； Pituitary Adenoma； PitNETs； Pituicytoma
摘要: 垂体神经内分泌肿瘤是颅内常见的肿瘤，2022年新版《WHO内分泌与神经内分泌肿瘤分类》的更新发生重大变化。与旧版相比，主要在于将使用“垂体腺瘤”更改为“垂体神经内分泌肿瘤”。判别方法为利用垂体转录因子及激素表达分类垂体肿瘤，以此归类肿瘤细胞谱系。
Abstract: Pituitary neuroendocrine tumors are common intracranial tumors, and the update of the new edi-tion of the WHO Classification of Endocrine and Neuroendocrine tumors has undergone significant changes. Compared with the old version, it is mainly to change the use of “pituitary adenoma” to “pituitary neuroendocrine tumor”. The discrimination method is to use pituitary transcription fac-tors and hormone expression to classify pituitary tumors into the tumor cell lineage.
文章引用：严佳乐, 苏晓梅, 马晓梅. 垂体神经内分泌肿瘤分类研究进展[J]. 临床医学进展, 2023, 13(7): 10924-10930. https://doi.org/10.12677/ACM.2023.1371525

参考文献

[1] Daly, A.F. and Beckers, A. (2020) The Epidemiology of Pituitary Adenomas. Endocrinology and Metabolism Clinics of North America, 49, 347-355. [Google Scholar] [CrossRef] [PubMed]
[2] Kontogeorgos, G. (2005) Classification and Pathology of Pituitary Tumors. Endocrine, 28, 27-35. [Google Scholar] [CrossRef] 
[3] Nishioka, H. and Inoshita, N. (2019) The 2017 WHO Classification of Pituitary Tumors. No Shinkei Geka, 47, 597-606.
[4] 燕羽佳, 刘佳雨, 阎晓玲, 等. 2017年WHO垂体肿瘤分类变化的解读与分析[J]. 中国微侵袭神经外科杂志, 2020, 25(11): 525-528.
[5] 刘涵. 垂体瘤患者临床特征、诊治及术后综合管理的探究[D]: [硕士学位论文]. 济南: 山东大学, 2021.
[6] Cohn, A., Li, C.Y.L., Hoffman, S.E., et al. (2021) Characterization of Gonadotroph Pituitary Adenomas Based on the Recent 2017 WHO Pituitary Tumor Classi-fication. Journal of the Endocrine Society, 5, A640-A641. [Google Scholar] [CrossRef] 
[7] Asa, S.L., Mete, O., Perry, A., et al. (2022) Overview of the 2022 WHO Classification of Pituitary Tumors. Endocrine Pathology, 33, 6-26. [Google Scholar] [CrossRef] [PubMed]
[8] Pérezlópez, C., Zamarrón, Á., Isla, A., et al. (2021) Is the Cur-rent WHO Classification of Pituitary Adenomas Practical? Endocrinologia, Diabetes y Nutricion, 69, 234-235.
[9] Asa, S.L., Mete, O., Cusimano, M.D., et al. (2021) Pituitary Neuroendocrine Tumors: A Model for Neuroendocrine Tumor Classification. Modern Pathology, 34, 1634-1650. [Google Scholar] [CrossRef] [PubMed]
[10] Asa, S.L., Asioli, S., Bozkurt, S., et al. (2020) Pituitary Neuroendocrine Tumors (PitNETs): Nomenclature Evolution, Not Clinical Revolution. Pituitary, 23, 322-325. [Google Scholar] [CrossRef] [PubMed]
[11] Rindi, G., Klimstra, D.S., Abedi-Ardekani, B., et al. (2018) A Common Classification Framework for Neuroendocrine Neoplasms: An Internation-al Agency for Research on Cancer (IARC) and World Health Organization (WHO) Expert Consensus Proposal. Modern Pathology, 31, 1770-1786. [Google Scholar] [CrossRef] [PubMed]
[12] Williams, M.D., Harris, R., Dayan, C.M., et al. (2009) Thyroid Function and the Natural History of Depression: Findings from the Caerphilly Prospective Study (CaPS) and a Meta-Analysis. Clinical Endocrinology, 70, 484-492. [Google Scholar] [CrossRef] [PubMed]
[13] Nasr, C., Mason, A., Mayberg, M., et al. (2006) Acromeg-aly and Somatotroph Hyperplasia with Adenomatous Transformation Due to Pituitary Metastasis of a Growth Hor-mone-Releasing Hormone-Secreting Pulmonary Endocrine Carcinoma. The Journal of Clinical Endocrinology and Me-tabolism, 91, 4776-4780. [Google Scholar] [CrossRef] [PubMed]
[14] Feola, T., Carbonara, F., Verrico, M., et al. (2022) Immunotherapy for Aggressive and Metastatic Pituitary Neuroendocrine Tumors (PitNETs): State-of-the Art. Cancers, 14, Article No. 4093. [Google Scholar] [CrossRef] [PubMed]
[15] Nie, D., Zhao, P., Li, C.Z., et al. (2022) Application of “Mosiac Sign” on T2-WI in Predicting the Consistency of Pituitary Neuroendocrine Tumors. Frontiers in Surgery, 9, Article ID: 922626. [Google Scholar] [CrossRef] [PubMed]
[16] 唐晓爽, 张晓青, 尹华春, 等. 无功能垂体腺瘤的垂体相关转录因子表达与临床特征分析[J]. 中国临床神经外科杂志, 2021, 26(12): 907-911.
[17] Manojlovic-Gacic, E., Eng-ström, B.E. and Casar-Borota, O. (2018) Histopathological Classification of Non-Func- tioning Pituitary Neuroendocrine Tumors. Pituitary, 21, 119-129. [Google Scholar] [CrossRef] [PubMed]
[18] Mete, O., Kefeli, M., Çalışkan, S. and Asa, S.L. (2019) GATA3 Immunoreactivity Expands the Transcription Factor Profile of Pituitary Neuroendocrine Tumors. Modern Pathology, 32, 484-489. [Google Scholar] [CrossRef] [PubMed]
[19] Ben-Shlomo, A., Deng, N., Ding, E., et al. (2020) DNA Damage and Growth Hormone Hypersecretion in Pituitary Somatotroph Adenomas. The Journal of Clinical Investigation, 130, 5738-5755. [Google Scholar] [CrossRef] 
[20] Wolfgang, S. (2021) WHO-Klassifikation der Hypophysen-tumoren des Jahres 2017. Der Pathologe, 42, 333-351. [Google Scholar] [CrossRef] [PubMed]
[21] Ho, K.K.Y., Gadelha, M., Kaiser, U.B., et al. (2022) The NET-ting of Pituitary Adenoma: A Gland Illusion. Pituitary, 25, 349-351. [Google Scholar] [CrossRef] [PubMed]
[22] Asa, S.L., et al. (2017) From Pituitary Adenoma to Pituitary Neuroendocrine Tumor (PitNET): An International Pituitary Pathology Club Proposal. Endocrine-Related Cancer, 24, C5-C8. [Google Scholar] [CrossRef] 
[23] Serioli, S., Doglietto, F., Fiorindi, A., et al. (2019) Pituitary Adenomas and Invasiveness from Anatomo-Surgical, Radiological, and Histological Perspectives: A Systematic Litera-ture Review. Cancers, 11, Article No. 1936. [Google Scholar] [CrossRef] [PubMed]
[24] Jiang, S.Z., Zhu, J.Y., Feng, M., et al. (2021) Clinical Profiles of Silent Corticotroph Adenomas Compared with Silent Gonadotroph Adenomas after Adopting the 2017 WHO Pituitary Classification System. Pituitary, 24, 564-573.
[25] Connor, S.E., Wilson, F. and Hogarth, K. (2014) Magnetic Reso-nance Imaging Criteria to Predict Complete Excision of Parasellar Pituitary Macroadenoma on Postoperative Imaging. Journal of Neurological Surgery. Part B, Skull Base, 75, 41-46. [Google Scholar] [CrossRef] [PubMed]
[26] Ilie, M.D., Vasiljevic, A., Bertolino, P., et al. (2022) Biological and Therapeutic Implications of the Tumor Microenvironment in Pituitary Adenomas. Endocrine Reviews, 44, 297-311. [Google Scholar] [CrossRef] [PubMed]
[27] Stefanidis, P., Kyriakopoulos, G., Seretis, A.M., et al. (2022) Prognostic Factors for Invasiveness and Recurrence of Pituitary Adeno-mas: A Series of 94 Patients. Diagnostics (Basel, Switzerland), 12, Article No. 2413. [Google Scholar] [CrossRef] [PubMed]
[28] Rosinha, P., Fonseca, L., Amaral, C., et al. (2022) Pituitary Ad-enomas in the Elderly: Retrospective Comparative Analysis of Clinical/Tumor Features and Surgical Data by Age Group. Medicine, 101, e30825. [Google Scholar] [CrossRef] 
[29] Zhang, F., Zhang, Q., Zhu, J., et al. (2022) Integrated Prote-ogenomic Characterization across Major Histological Types of Pituitary Neuroendocrine Tumors. Cell Research, 32, 1047-1067. [Google Scholar] [CrossRef] [PubMed]
[30] Guaraldi, F., Morandi, L., Zoli, M., et al. (2022) Epigenomic and Somatic Mutations of Pituitary Tumors with Clinical and Pathological Correlations in 111 Patients. Clin-ical Endocrinology, 97, 763-772. [Google Scholar] [CrossRef] [PubMed]
[31] Hickman, R.A., Bruce, J.N., Otten, M., et al. (2021) Gonadotroph Tumours with a Low SF-1 Labelling Index Are More Likely to Recur and Are Associated with Enrichment of the PI3K-AKT Pathway. Neuropathology and Applied Neurobiology, 47, 415-427. [Google Scholar] [CrossRef] [PubMed]
[32] Mcdonald, W.C., Banerji, N., Mcdonald, K.N., et al. (2017) Steroidogenic Factor 1, Pit-1, and Adrenocorticotropic Hormone: A Rational Starting Place for the Immunohistochemical Characteriza-tion of Pituitary Adenoma. Archives of Pathology & Laboratory Medicine, 141, 104-112. [Google Scholar] [CrossRef] 
[33] Sjöstedt, E., Bollerslev, J., Mulder, J., et al. (2017) A Specific Antibody to Detect Transcription Factor T-Pit: A Reliable Marker of Corticotroph Cell Differentiation and a Tool to Im-prove the Classification of Pituitary Neuroendocrine Tumours. Acta Neuropathologica, 134, 675-677. [Google Scholar] [CrossRef] [PubMed]
[34] Burcea, I.F., Năstase, V.N. and Poiană, C. (2021) Pituitary Tran-scription Factors in the Immunohistochemical and Molecular Diagnosis of Pituitary Tumours—A Systematic Review. Endokrynologia Polska, 72, 53-63. [Google Scholar] [CrossRef] 
[35] Trouillas, J., Jaffrain-Rea, M.L., Vasiljevic, A., et al. (2020) Are Ag-gressive Pituitary Tumors and Carcinomas Two Sides of the Same Coin? Pathologists Reply to Clinician’s Questions. Reviews in Endocrine & Metabolic Disorders, 21, 243-251. [Google Scholar] [CrossRef] [PubMed]
[36] Trouillas, J., Jaffrain-Rea, M.L., Vasiljevic, A., et al. (2020) How to Classify the Pituitary Neuroendocrine Tumors (PitNET)s in 2020. Cancers, 12, Article No. 514. [Google Scholar] [CrossRef] [PubMed]

为你推荐